DOCETAXEL
PeakNDAINJECTIONINJECTABLE
Approved
Mar 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
DOCETAXEL by Pfizer is 12. Approved for metastatic breast cancer after failure of prior chemotherapy, metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy, locally advanced and 2 more indications. First approved in 2014.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Docetaxel is a small-molecule taxane chemotherapy agent that stabilizes microtubules and inhibits mitosis in cancer cells. It is indicated for metastatic breast cancer, non-small cell lung cancer (including gastroesophageal junction adenocarcinoma), and prostate cancer after failure of prior chemotherapy. The drug works by binding to tubulin, promoting microtubule assembly while blocking disassembly, thereby halting cell division.
Peak
Product is at peak market penetration with mature competitive dynamics; commercial teams are focused on market defense and margin optimization rather than growth.
Mechanism of Action
12.1 Mechanism of Action Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously…
Worked on DOCETAXEL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.